1. Home
  2. BTAI vs AP Comparison

BTAI vs AP Comparison

Compare BTAI & AP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BTAI
  • AP
  • Stock Information
  • Founded
  • BTAI 2017
  • AP 1929
  • Country
  • BTAI United States
  • AP United States
  • Employees
  • BTAI N/A
  • AP N/A
  • Industry
  • BTAI Biotechnology: Pharmaceutical Preparations
  • AP Fluid Controls
  • Sector
  • BTAI Health Care
  • AP Industrials
  • Exchange
  • BTAI Nasdaq
  • AP Nasdaq
  • Market Cap
  • BTAI 52.7M
  • AP 62.7M
  • IPO Year
  • BTAI 2018
  • AP N/A
  • Fundamental
  • Price
  • BTAI $3.01
  • AP $2.51
  • Analyst Decision
  • BTAI Buy
  • AP
  • Analyst Count
  • BTAI 5
  • AP 0
  • Target Price
  • BTAI $32.80
  • AP N/A
  • AVG Volume (30 Days)
  • BTAI 5.2M
  • AP 43.0K
  • Earning Date
  • BTAI 11-13-2025
  • AP 11-10-2025
  • Dividend Yield
  • BTAI N/A
  • AP N/A
  • EPS Growth
  • BTAI N/A
  • AP N/A
  • EPS
  • BTAI N/A
  • AP N/A
  • Revenue
  • BTAI $868,000.00
  • AP $414,471,000.00
  • Revenue This Year
  • BTAI N/A
  • AP N/A
  • Revenue Next Year
  • BTAI $614.78
  • AP N/A
  • P/E Ratio
  • BTAI N/A
  • AP N/A
  • Revenue Growth
  • BTAI N/A
  • AP N/A
  • 52 Week Low
  • BTAI $1.17
  • AP $1.61
  • 52 Week High
  • BTAI $13.28
  • AP $3.99
  • Technical
  • Relative Strength Index (RSI)
  • BTAI 41.66
  • AP 35.22
  • Support Level
  • BTAI $2.86
  • AP $2.63
  • Resistance Level
  • BTAI $3.95
  • AP $2.66
  • Average True Range (ATR)
  • BTAI 0.34
  • AP 0.11
  • MACD
  • BTAI -0.17
  • AP -0.01
  • Stochastic Oscillator
  • BTAI 11.89
  • AP 7.55

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

About AP Ampco-Pittsburgh Corporation

Ampco-Pittsburgh Corp is manufacturing and selling engineered, specialty metal products and customized equipment. It operates in two business segments namely the Forged and Cast Engineered Products segment and the Air and Liquid Processing segment. The Forged and Cast Engineered Products segment produces forged hardened steel rolls, cast rolls, and open-die forged products. Forged hardened steel rolls are used in cold rolling mills by producers of steel, aluminum, and other metals whereas, the Air and Liquid Processing segment includes Aerofin, Buffalo Air Handling, and Buffalo Pumps. The company generates a majority of its revenue from the Forged and Cast Engineered Products segment. It has a business presence in the United States and other countries.

Share on Social Networks: